List view / Grid view
Long-term data in treatment-naïve patients highlight Stribild’s sustained efficacy, safety…
16 October 2013 | By Gilead
Long-term data in treatment-naïve patients highlight Stribild’s sustained efficacy, safety and tolerability profile...
New U.S. labeling for ISENTRESS® (raltegravir) to include 240-week results…
1 July 2013 | By Merck
New U.S. labeling for ISENTRESS® (raltegravir) to include 240-week results from STARTMRK study...
Gilead Sciences announced that the European Commission has granted marketing…
28 May 2013 | By Gilead Sciences
Gilead Sciences announced that the European Commission has granted marketing authorization for Stribild®...
Two-year results announced ...
15 November 2012 | By Gilead Sciences
Two-year results announced ...
The U.S. FDA approved a labeling update for ISENTRESS® Film-coated…
21 May 2012 | By Merck
The U.S. FDA approved a labeling update for ISENTRESS® Film-coated Tablets to include 156-week data from the STARTMRK study...
Exploratory pre-specified analyses from the ongoing STARTMRK Phase III study…
13 October 2011 | By Merck
Exploratory pre-specified analyses from the ongoing STARTMRK Phase III study results...
